Taysha Gene Therapies, Inc.

TSHA Nasdaq SEC CIK 1806310
Follow Taysha Gene Therapies Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$39.1M −19.5% vs same quarter last year
EPS, diluted −$0.10 −11.1% vs same quarter last year
Operating cash flow −$32.9M −36.2% vs same quarter last year
Revenue by quarter
$2M
$2.3M
$2M
$0
$5.5M
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−$200M−$150M−$100M−$50M$0$50MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$9.8M−$109M
FY24$8.3M−$89.3M
FY23$15.5M−$111.6M
FY22$2.5M−$166M
FY21-−$174.5M
FY20-−$60M
FY19--
MarginsShare of revenue
  • Operating margin
  • Net margin
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−1130.6%−1115.3%
FY24−1097.6%−1071.6%
FY23−468.8%−722.1%
FY22−6492.7%−6635.3%
FY21--
FY20--
FY19--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$93.8M
FY24−$81.6M
FY23−$76.9M
FY22−$109M
FY21−$132.3M
FY20−$30.8M
FY19-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Taysha Gene Therapies
  • Healthcare median
−8000%−6000%−4000%−2000%0%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearTaysha Gene TherapiesHealthcare median
FY25−1115.3%−30.6%
FY24−1071.6%−47%
FY23−722.1%−58%
FY22−6635.3%−80.4%
FY21-−71.8%
FY20-−62.2%
FY19-−46.2%